VectivBio is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. VectivBio’s product candidate, apraglutide*, is a next-generation, long-acting glucagon-like peptide-2 (GLP-2) analog being studied in the global Phase 3 STARS trial for the treatment of short bowel syndrome with intestinal failure (SBS-IF).

*Apraglutide is an investigational agent and is not approved in any region.